undamentalytics Newsletter

Kirk Randal J: insider trades

Chief executive, Officer, Director, 10% owner at 9 companies we cover. 45 open-market purchases and 16 sales not made under a pre-set plan, reported from February 7, 2011 to March 31, 2026.

Would copying Kirk Randal J’s purchases have beaten the S&P 500?

Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on February 8, 2011 into $1,240 by November 2, 2026, −12.4% a year. The copy held shares only 54% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $28,283, +6.8% a year (the S&P 500 held throughout made $75,175, +13.7% a year). Beta against the index was 0.93. Twelve months after each report, the average purchase was −28.2% against the S&P 500 (median −39.7%), and 13% beat it: within what luck alone would produce (p = 0.19 over 8 years). Measured from the trade date, the insider’s own timing, the average was −22.7%. After their sales, the shares moved −10.2% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$25.0k$50.0k$75.0k 20112013201520172019202120232025 $75.2k$28.3k$1.2k
Copying Kirk Randal JS&P 500, same days investedS&P 500, held throughout $10,000 copying Kirk Randal J’s open-market purchases from February 8, 2011, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−12.4%
S&P 500, same days invested
+6.8% (held throughout +13.7%)
Time in shares
54%
Sharpe ratio (S&P 500)
0.04 (0.74)
Biggest drop (S&P 500)
−98% (−34%)
Market sensitivity (beta)
0.93
Purchases copied
23

Trade by trade

Kirk Randal J: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 23 −0.5% +4.1% 57% 8 −0.40 0.70 No reliable evidence
Purchases, 6 months after the report 23 −9.1% −15.5% 26% 8 −1.67 0.14 No reliable evidence
Purchases, 12 months after the report 23 −28.2% −39.7% 13% 8 −1.44 0.19 No reliable evidence
Purchases, 12 months after the trade 20 −22.7% −35.0% 10% 8 −1.15 0.29 No reliable evidence
Sales, 3 months after the report 6 −3.3% −3.2% 83% 1 — — Not enough years
Sales, 12 months after the report 6 −10.2% −10.3% 100% 1 — — Not enough years
Sales, 12 months after the trade 6 −11.2% −11.3% 100% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Precigen, Inc. PGEN Executive Chairman305March 31, 2014March 31, 2026
Halozyme Therapeutics, Inc. HALO —66August 11, 2011August 28, 2018
Alaunos Therapeutics, Inc. TCRT —30February 7, 2011January 23, 2012
Precipio, Inc. PRPO —12January 11, 2016August 30, 2018
Aquabounty Technologies Inc AQB —21February 18, 2020November 24, 2021
Theriva Biologics, Inc. TOVX —20October 31, 2012September 4, 2015
Oragenics Inc OGEN —10November 22, 2013November 22, 2013
Armata Pharmaceuticals, Inc. ARMP —01December 29, 2016December 29, 2016
Soligenix, Inc. SNGX —01May 8, 2017May 8, 2017

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 31, 2026March 30, 2026 PGEN Sale $15,750,177 not yetnot yetnot yet
December 22, 2025December 22, 2025 PGEN Sale $7,942,150 not yetnot yetnot yet
November 21, 2025November 19, 2025 PGEN Sale $12,291,748 not yetnot yetnot yet
September 30, 2025September 30, 2025 PGEN Sale $6,170,964 not yetnot yetnot yet
September 19, 2025September 18, 2025 PGEN Sale $18,653,532 not yetnot yetnot yet
August 13, 2024August 9, 2024 PGEN Purchase $19,999,999 not yetnot yetnot yet
December 29, 2023December 28, 2023 PGEN Purchase $136,327 not yetnot yetnot yet
August 17, 2023August 15, 2023 PGEN Purchase $757,612 not yetnot yetnot yet
January 31, 2023January 27, 2023 PGEN Purchase $19,999,999 not yetnot yetnot yet
November 24, 2021November 23, 2021 AQB Sale $27,048,000 not yetnot yetnot yet
November 23, 2021November 19, 2021 PGEN Purchase $3,634,787 not yetnot yetnot yet
August 13, 2020August 11, 2020 PGEN Purchase $5,346,020 not yetnot yetnot yet
August 13, 2020August 11, 2020 AQB Purchase $10,000,000 not yetnot yetnot yet
March 20, 2020March 19, 2020 PGEN Purchase $2,241,625 not yetnot yetnot yet
February 18, 2020February 13, 2020 AQB Purchase $7,762,500 not yetnot yetnot yet
February 4, 2020January 31, 2020 PGEN Purchase $34,999,999 not yetnot yetnot yet
June 10, 2019June 6, 2019 PGEN Purchase $2,534,162 +4.1%−39.7%−54.3%
June 10, 2019June 6, 2019 PGEN Purchase $1,689,443 +4.1%−39.7%−54.3%
June 4, 2019May 31, 2019 PGEN Purchase $998,269 −2.4%−54.3%not yet
June 4, 2019May 31, 2019 PGEN Purchase $665,516 −2.4%−54.3%not yet
May 30, 2019May 29, 2019 PGEN Purchase $2,351,703 not yetnot yetnot yet
May 30, 2019May 29, 2019 PGEN Purchase $1,567,799 not yetnot yetnot yet
May 24, 2019May 22, 2019 PGEN Purchase $1,921,203 not yetnot yetnot yet
May 24, 2019May 22, 2019 PGEN Purchase $1,280,804 not yetnot yetnot yet
May 21, 2019May 17, 2019 PGEN Purchase $2,949,096 not yetnot yetnot yet
May 21, 2019May 17, 2019 PGEN Purchase $1,966,075 not yetnot yetnot yet
May 15, 2019May 13, 2019 PGEN Purchase $5,532,056 not yetnot yetnot yet
May 15, 2019May 13, 2019 PGEN Purchase $3,688,026 not yetnot yetnot yet
August 30, 2018August 28, 2018 PRPO Sale $10,086 not yetnot yetnot yet
August 28, 2018August 24, 2018 HALO Sale $11,663,346 −7.7%−12.2%−13.8%
August 23, 2018August 21, 2018 HALO Sale $21,085,138 −2.5%−13.8%−8.4%
August 16, 2018August 14, 2018 HALO Sale $8,476,983 −1.9%−7.9%−11.4%
August 10, 2018August 8, 2018 HALO Sale $9,937,299 −6.8%−10.9%−12.5%
July 27, 2018July 25, 2018 HALO Sale $5,221,414 −3.9%−9.7%−11.3%
July 6, 2018July 3, 2018 PGEN Purchase $99,999,992 +6.0%−57.8%−58.3%
June 29, 2018June 27, 2018 HALO Sale $5,186,692 +2.8%−6.7%−9.8%
January 22, 2018January 19, 2018 PGEN Purchase $12,500,000 +33.1%−39.3%−33.7%
August 14, 2017August 11, 2017 PGEN Purchase $2,499,981 −37.8%−42.7%−46.0%
June 12, 2017June 8, 2017 PRPO Sale $1,975,000 not yetnot yetnot yet
May 8, 2017May 4, 2017 SNGX Sale $501,882 not yetnot yetnot yet
December 29, 2016December 27, 2016 ARMP Sale $84,375 not yetnot yetnot yet
December 14, 2016December 13, 2016 PGEN Purchase $1,000,113 −31.9%−75.6%−73.1%
May 16, 2016May 13, 2016 PGEN Purchase $1,000,574 +0.3%−27.5%−13.4%
January 11, 2016January 6, 2016 PRPO Purchase $4,474,825 not yetnot yetnot yet
December 14, 2015December 11, 2015 PGEN Purchase $3,715,800 +16.1%−21.0%−19.2%
December 7, 2015December 7, 2015 PGEN Purchase $7,289,642 +10.9%−18.4%−9.6%
September 4, 2015September 2, 2015 TOVX Purchase $3,000,000 not yetnot yetnot yet
January 27, 2015January 27, 2015 PGEN Purchase $15,000,012 +23.2%+3.6%−8.9%
May 13, 2014May 9, 2014 PGEN Purchase $990,007 +23.8%+119.9%+158.9%
March 31, 2014March 27, 2014 PGEN Purchase $6,249,986 −8.5%+58.0%+50.1%
November 22, 2013November 20, 2013 OGEN Purchase $3,106,225 not yetnot yetnot yet
October 31, 2012October 29, 2012 TOVX Purchase $5,000,000 not yetnot yetnot yet
June 5, 2012June 1, 2012 HALO Purchase $1,433,755 −36.1%−48.1%−43.9%
May 17, 2012May 15, 2012 HALO Purchase $7,951,403 −34.2%−40.0%−20.4%
February 13, 2012February 10, 2012 HALO Purchase $14,429,600 −35.1%−63.5%−61.1%
January 23, 2012January 20, 2012 TCRT Purchase $9,999,990 −8.6%−34.8%−36.3%
November 23, 2011November 21, 2011 HALO Purchase $2,230,109 +26.3%−56.3%−49.2%
November 16, 2011November 14, 2011 HALO Purchase $5,211,428 +23.9%−49.3%−45.0%
August 22, 2011August 18, 2011 TCRT Purchase $2,272,821 −17.8%−22.6%not yet
August 11, 2011August 9, 2011 HALO Purchase $5,945,417 +17.7%−33.5%−23.8%
February 7, 2011February 3, 2011 TCRT Purchase $10,982,500 +13.8%−11.3%−12.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Kirk Randal J traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.